Nigericin Promotes NLRP3-Independent Bacterial Killing in Macrophages

Heather Armstrong1,2†, Michael Bording-Jorgensen2,3†, Richard Chan2,3 and Eytan Wine1,2,3*

1 Department of Pediatrics, University of Alberta, Edmonton, AB, Canada, 2 Centre of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR), University of Alberta, Edmonton, AB, Canada, 3 Department of Physiology, University of Alberta, Edmonton, AB, Canada

Altered microbiota has been associated with a number of diseases, including inflammatory bowel diseases, diabetes, and cancer. This dysregulation is thought to relate the host inflammatory response to enteric pathogens. Macrophages play a key role in host response to microbes and are involved in bacterial killing and clearance. This process is partially mediated through the potassium efflux-dependent, cytosolic, PYCARD-containing inflammasome protein complex. Surprisingly, we discovered an alternative mechanism for bacterial killing, independent of the NLRP3 inflammasome/PYCARD. Using the NLRP3 inflammasome-deficient Raw 264.7 and PYCARD-deficient J77 macrophages, which both lack PYCARD, we found that the potassium efflux activator nigericin enhances bacterial killing. Macrophage response to nigericin was examined by RT gene profiling and subsequent qPCR, which demonstrated altered expression of a series of genes involved in the IL-18 bacterial killing pathway. Based on our results we propose a model of bacterial killing, unrelated to NLRP3 inflammasome activation in macrophage cells. Improving understanding of the molecular pathways driving bacterial clearance within macrophage cells will aid in the development of novel immune-targeted therapeutics in a number of diseases.

Keywords: NLRP3, inflammasome, inflammatory bowel diseases, Citrobacter rodentium, nigericin

INTRODUCTION

Dysbiosis or altered microbiota, is characteristic of a number of diseases including inflammatory bowel diseases (IBD), obesity, diabetes, autism, and cancer (1), likely mediating a dysregulation of the host immune response (2–4). Detailed analysis of the intestinal inflammatory response to enteric pathogens may be key to understanding disruption of homeostasis and disease progression and discovering novel therapies.

Interestingly, bacterial DNA can stimulate activation of host innate immune cells through recognition of pattern-recognition molecules (PRMs) by microbe-associated molecular patterns (MAMPs) (5–7). PRMs are located on or within innate immune cells such as dendritic cells, macrophages, and neutrophils, along with epithelial cells. Examples of transmembrane PRMs are toll-like receptors (TLRs) and C-type lectins (CLRs); cytosolic PRMs include members of the NOD (Nucleotide Oligomerization Domain)-like receptor (NLR) family and DNA sensing DAI and AIM2 complexes (8). Macrophages are especially pivotal for a functional immune response as they are involved in bacterial killing and clearance by engulfing and eradicating invading pathogens (9). We have previously demonstrated that bacterial clearance by macrophages can...
be improved through the stimulation of the multiprotein complex known as the inflammasome, through extracellular ATP (10). Increased bacterial clearance from ATP activation was associated with a reduction of pro-inflammatory cytokines after clearance, suggesting a potential mechanism for the link between increased susceptibility to IBD and inflammasome dysfunction (10, 11).

A number of inflammasomes have been identified, including NLRP1, NLRP2, NLRP3, and NLRC4 (12). The most well-characterized inflammasome is NLRP3, in which NLRP3 forms a complex with PYCARD [also known as the adapter protein apoptosis-associated speck-like protein (ASC)] and procaspase-1 (13, 14). Assembly of this complex results in self-cleavage of procaspase-1 to active caspase-1 (15), leading to the activation of the proinflammatory cytokines interleukin (IL)-1β and IL-18 (8, 16–18). NLRP3 activation involves a two-step process including a priming signal, which includes recognition of MAMPs (e.g., bacteria or lipopolysaccharide) by cell surface TLRs, followed by a second step involving NLRP3 complex assembly and activation (12, 19–22). Activation of the inflammasome is driven by agonists such as adenosine triphosphate (ATP), which indirectly regulates NLRP3 activity via stimulation of P2X7 nonselective K+ or Ca2+ channel receptors (8).

While inflammasome modulators such as Nigericin are described as NLRP3-specific (23), their indirect effects led us to hypothesize that they may be able to regulate inflammation and bacterial killing via inflammasome-independent mechanisms. Nigericin is a toxin derived from Streptomyces hygroscopicus. It is described as a potassium ionophore, which facilitates H+/K+ anti-port across cell membranes, thereby activating NLRP3 by causing potassium efflux. In this in vitro study, we examined the effects nigericin, an NLRP3 activator, on Raw 264.7 macrophages, which lack PYCARD/ASC and therefore are incapable of NLRP3 activation. As Raw 264.7 cells are a murine cell culture model, we implemented the mouse pathogen Citrobacter rodentium for our in vitro experiments. C. rodentium shares many virulence factors such as formation of attaching/effacing (A/E) lesions with the commonly studied human intestinal Escherichia coli pathogenic strains Enterohaemorrhagic E. coli (EHEC) and Enteropathogenic E. coli (EPEC), resulting in transmissible colonic hyperplasia, colitis, and bloody diarrhea (24, 25). Our results demonstrate that the NLRP3 agonist nigericin, promotes killing of C. rodentium, and induction of an inflammatory response through pathways unassociated with the NLRP3 inflammasome complex, independent of ASC. Understanding this previously unrecognized mechanism of bacterial clearance within a macrophage cell system will aid in the ability to identify new methods of altering the immune response in a number of human diseases driven by altered host-microbe interactions, such as IBD.

MATERIALS AND METHODS

Cell Culture

Murine macrophage cell line Raw 264.7 were obtained from the American Type Culture Collection (ATCC; Maryland, United States) and cultured in Dulbecco’s Modified Eagle Medium (DMEM), 10% fetal bovine serum (FBS), 5% penicillin/streptomycin and incubated (37°C, 5% CO2) until confluent for a maximum of 20 passages.

Murine macrophage cell line J774A.1 were obtained from the ATCC and cultured in DMEM containing 10% FBS for a maximum of 25 passages.

C. rodentium (strain DBS100) was provided as a gift by Dr. Philip Sherman (University of Toronto) and cultured aerobically in lysogeny broth (LB) at 37°C.

Standard Curves

Raw 264.7 cells were seeded at 1.5 × 10^5 cells per well in a 24 well plate and cultured overnight at 37°C and 5% CO2. Cells were treated as indicated below with ATP (Sigma), Ac-Tyr-Val-Ala-Asp-Chloromethylketone (YVAD; Sigma), nigericin (Sigma), or Gentamicin (Fischer Scientific) to determine associated toxicity or growth inhibition. Cells were manually counted using a haemocytometer and trypan blue exclusion technique to determine cell number at the indicated time points.

C. rodentium liquid LB cultures were seeded and grown overnight at 37°C. Growth density was measured at OD600 on a spectrophotometer and serial dilutions were cultured on LB agar overnight. Colony counts were performed on each plate and used to calculate colony forming units (CFU)/mL from each dilution.

C. rodentium liquid LB cultures treated with nigericin (20 µM) were seeded and grown overnight at 37°C. Cells were diluted to an OD600 of 0.1 (representing 8 × 10^7 CFUs/mL) and treated with nigericin at time 0 h. Growth density was measured at OD600 on a spectrophotometer at indicated time points and compared to untreated growth.

siRNA

Raw 264.7 or J77 cells were plated (8 × 10^4 cells per well) in 24 well plates overnight at 37°C and 5% CO2 to adhere. Cells were then treated with siRNA as indicated or scramble siRNA control using Lipofectamine 2,000 by manufacturer’s instructions. Hundred pmol of siRNA was used to efficiently knock down p38 (Dharmacon; AUGAGGAGAUGACCGGAUA) and IFNγ (Dharmacon; UCGAAUGAUCAGGAUGUA), or 50 pmol siRNA phosphorylated ASC as demonstrated by western blotting following 48 h siRNA.

Gentamicin Protection Assay

Raw 264.7 or J77 cells were seeded into a 24-well plate overnight at a density of 2 × 10^5 cells per well. Medium was removed and replaced with serum-free DMEM prior to beginning treatment. Cells were then treated with either YVAD (10 µM) and/or nigericin (20 µM), as detailed in Figure 1A. Treatment with YVAD occurred 1 h prior to C. rodentium inoculation and proceeded for 3 h total. Raw 264.7 macrophages were inoculated with C. rodentium [multiplicity of infection (MOI) 1:10] 1 h after YVAD (when appropriate) for 2 h total. Nigericin treatment or ATP control (2.5 mM) was added 1.5 h post-infection and proceeded for 30 min total. Both non-infected and infected, no treatment (NT) controls were included. Medium was removed and 20 µg/mL of gentamicin was added to each well for 3 h to kill any bacteria not engulfed by the macrophages
(gentamicin does not penetrate the eukaryotic cell membrane). Cells were lysed with 1% TritonX-100 for 30 min to enumerate intracellular/engulfed bacteria. Lysates were plated on LB agar in serial dilutions and colonies were manually counted the following day to calculate intracellular CFU/mL. Results were repeated again following pre-treatment with siRNA directed toward p38, Interferon gamma (IFNγ), both p38 and IFNγ, or ASC as indicated. Further results were repeated using the NLRP3 inhibitor MCC950 (Invivogen) at 1 µM for 3 h prior to infection with *C. rodentium* and nigericin treatment as previously performed.

**ELISA**

Raw 264.7 or J77 cells were seeded at a density of 2 × 10⁵ cells per well into a 24-well plate and grown overnight. Medium was removed and replaced with serum-free DMEM prior to beginning treatment. J77 cells were included as a positive active-NLRP3 control. Cells were then treated with YV AD prior to beginning treatment. J77 cells were included as a positive control for infection with *C. rodentium*.

Medium was removed and replaced with serum-free DMEM (gentamicin does not penetrate the eukaryotic cell membrane). Cells were lysed with 1% TritonX-100 for 30 min to enumerate intracellular/engulfed bacteria. Lysates were plated on LB agar in serial dilutions and colonies were manually counted the following day to calculate intracellular CFU/mL. Results were repeated again following pre-treatment with siRNA directed toward p38, Interferon gamma (IFNγ), both p38 and IFNγ, or ASC as indicated. Further results were repeated using the NLRP3 inhibitor MCC950 (Invivogen) at 1 µM for 3 h prior to infection with *C. rodentium* and nigericin treatment as previously performed.

**Western Blot**

Lysates were collected by applying 150 µl RIPA buffer to each well. Cells were removed by aggressive pipetting and centrifuged at 14,000 g for 10 min to remove any bacteria, cells, or debris. Cell lysates were collected by applying 150 µl radioimmunoprecipitation assay (RIPA) buffer to each well. Cells were removed by aggressive pipetting and centrifuged at 14,000 g for 10 min to remove cell debris. Total protein levels were determined by Bradford assay and 25 µl total protein was loaded per sample into a BioRad 12% precast TGX acrylamide gel. Nitrocellulose membranes were probed for Mapk11 (Abcam; ab133566), lamin (Proteintech; 66095-1), ASC (Abcam; ab70627), and actin (Santa Cruz; sc-1616). Membranes were imaged using the BioRad ChemiDoc Gel Imaging System.

**Phagocytosis Assay**

Raw 264.7 cells were prepared as described for the gentamicin protection assay. In order to dissociate phagocytosis from bacterial invasion of Raw 264.7 cells, we used inert beads to measure effects on phagocytosis alone; 1:10 (Raw 264.7 cells: beads) of 2 µm conjugated beads (Polysciences Inc.) were added to the culture for 2 h. Cells were treated as previously described and fixed using 4% paraformaldehyde, then stained with β-actin primary antibody (1:40; Abcam) and DAPI (1:1,000; Thermo Fischer). Slides were examined using an Olympus IX-81 microscope with a Yokagawa spinning disk confocal head, 60X oil immersion lens with a 1.42 numerical aperture, and a Hamamatsu EMCCD camera. Images were taken with equal exposure time without saturation and analyzed with Velocity imaging software (PerkinElmer). Illustrations were formatted, for noise reduction and increased sharpness, using Image J (National Institute of Health, Maryland, USA). Phagocytosis was measured by the number of beads inside the macrophages divided by the total number of macrophages in each randomly selected image. Ten photos of each treatment were taken from duplicate repeats.

**RNA Isolation and Gene Expression Analysis**

Raw 264.7 cells were cultured overnight prior to treatment as indicated. RNA was isolated using 1 mL trizol as previously described (26). Reverse transcription was performed using iScript master mix. Inflammatory cytokines and receptors RT² profile array (QIAGEN) was run using a BioRad CFX96 thermocycler according to manufacturer's instructions (40 cycles of 95°C to 60°C). RT-qPCR was performed as previously described (26) to validate findings using the primers highlighted in **Table 1**. Both biological and technical replicates were performed on all reactions using β Actin and Rer1 as housekeeping genes. Data were analyzed using CFX Manager Software Version 3.0 (Bio-Rad Laboratories, Inc.).

**Statistical Analysis**

Groups were compared using paired Student's *t*-test (two-tailed) analysis in Microsoft Excel or evaluated by the Student's unpaired *t*-test with Welch's correction using GraphPad Prism.
RESULTS
Optimization of Bacterial Growth and Assessment of Cell Toxicity
Response of Raw 264.7 cells to select non-toxic doses of ATP, YVAD, nigericin, and gentamicin was examined by culture growth curves (Supplementary Figure 1). Raw 264.7 cells were seeded at $1 \times 10^5$ cell per well in 24 well-plates and grown overnight before beginning treatment at indicated doses. Effects of each treatment on cell proliferation and death was calculated by manual counting at indicated time points using a haemocytometer (expressed as number of cells/well) and trypan blue exclusion (shown as % of cell death). The following doses with minimal effect on cell growth or survival (similar to dose zero) were selected for further study: 2.5 mg/mL ATP, 10 µM YVAD, 20 µM nigericin, and 20 µM gentamicin.

![Graph showing bacterial survival over time with different treatments](image)

**FIGURE 1** | Nigericin improves bacterial killing of *C. rodentium* independent from the NLRP3 inflammasome. (A) Raw264.7, J77ASC−/−, or J77scramble, cells were first treated with YVAD as indicated for a total of 3h. Inoculation of cell culture with *C. rodentium* (MOI 1:10) occurred 1h after initial addition of YVAD. 1.5h after *C. rodentium* inoculation, Nigericin (20 µM) or ATP control (25 mg/mL) was added to the culture media. Gentamicin (25 µg/mL) was used to eliminate non-invasive bacteria in (B) Raw264.7 cells or (C) J77ASC−/−, and J77scramble, and (D) cells treated with or without MCC950 (1 µM). Cell lysates were collected and grown on LB agar overnight and colonies were manually counted and expressed as CFU/mL. Values represent mean ± SEM between 3 independent experiments; *p < 0.05. YVAD (Ac-Tyr-Val-Ala-Asp-Chloromethylketone); MOI (multiplicity of infection); CFU (colony forming units).
Growth rates of *C. rodentium* in LB medium in overnight culture was evaluated by standard curve based on OD_{600} readings performed at 24 h post inoculation, compared to manual colony counts performed on serial dilutions of culture grown on LB plates (Supplementary Figure 2A). A trend line was fitted to the scatter plot and followed the formula \[ y = 2.7537x + 0.374 \], which was then used to determine the concentration of *C. rodentium* within culture, based on the optical density.

Given the potential toxicity of high doses of Gentamicin to Raw 264.7 cells, we optimized treatment duration. To examine the effects of gentamicin on microbial killing of *C. rodentium* cultured with Raw 264.7 cells, overnight cultures were prepared and infected as indicated in the methods section. To ensure the selected dose of gentamicin (25 µg/mL) resulted in effective microbial killing of extracellular *C. rodentium*, we plated culture supernatant on LB agar prior to lysing cells (data not shown). No growth of *C. rodentium* was found on LB agar following 24 h incubation. Cells were treated with gentamicin and lysed at 2, 4, 6, and 24 h and culture lysates were plated on LB agar. Following overnight growth, colonies were manually counted and expressed as CFU/mL (Supplementary Figure 2B). Results demonstrated that CFU/mL decreased by ∼75% between 2 and 4 h. While there was no significant change in CFU/mL between 4 and 6 h, a further reduction in CFU/mL occurred between 6 and 24 h. Subsequent experiments utilized gentamicin for 2 and/or 4 h to ensure that only *C. rodentium* cultures taken up by macrophages and not extracellular microbes were being examined.

**Microbial Killing of *C. rodentium* in Raw 264.7 Is Increased by Nigericin**

To examine the effects of nigericin on bacterial killing, Raw 264.7 cells were treated with nigericin (20 µM; 30 min), ATP (2.5 mM; 30 min), or Ac-YVAD-cmk (10 µM; 3 h; Sigma), in the presence of *C. rodentium* as indicated (Figure 1A). Raw 264.7 cells were inoculated with *C. rodentium* without any treatment (NT) as a negative control, or with ATP as a positive control (Figure 1A). Nigericin treatment of Raw 264.7 cells cultured with *C. rodentium* resulted in ∼70% reduction in CFU/mL compared to control not treated (NT) cultures (p < 0.05; Figure 1B). ATP led to a similar reduction in bacterial invasion compared to NT (p < 0.01). No significant change was found between YVAD and NT (p > 0.1) or nigericin+YVAD and NT (p > 0.1), suggesting that addition of YVAD (caspase-1 inhibition)
was able to counteract the bacterial killing effects of nigericin. Results were repeated in J77 cells following siRNA knock down of ASC (Figure 1C) and demonstrated equivalent findings. To ensure the effects of nigericin were not dependent on NLRP3 we repeated these experiments in all cell lines with and without nigericin, and similarly, with and without the NLRP3 inhibitor MCC950. Results demonstrated that MCC950 did not alter bacterial killing in Raw264.7 or J77ASC−/− cell lines in either NT or nigericin treated, C. rodentium infected cells (Figure 1D). Interestingly, in J77 cells, MCC950 did not affect bacterial killing in nigericin treated cells but reduced the bacterial killing in NT infected cells, suggesting that while NLRP3 clearly plays a role in bacterial killing, nigericin's effects are also seen through alternate pathways.

To test whether microbial killing occurred through activation of the NLRP3 inflammasome, Raw 264.7 and J77 cells were treated as indicated (Figure 1A) and supernatants were collected for ELISA to examine levels of secreted IL-1β, the main outcome of inflammasome activation. J77 macrophage cells were used as a positive control as this cell line expresses ASC (27). Only J77-activated macrophages displayed secretion of IL-1β, indicating that microbial killing was independent of NLRP3 in Raw 264.7 macrophages (Figure 2A). We further analyzed secretion of IL-18, an alternate pathway involved in bacterial killing (Figure 2B). These results demonstrate that Nigericin treatment increased secretion of IL-18 in Raw 264.7 cells while ATP promoted IL-18 secretion in J77 control cells. Analysis of cell lysates demonstrated that there was no altered expression of total IL-1β or IL-18 (Supplementary Figures 3A, B) as neither RNA or cytosolic levels change yet secretion was altered. Results were replicated in J77ASC−/− cells and demonstrated similar response to treatment compared to ASC-deficient Raw264.7 cells (Figures 2C, D). Knock down of ASC reduced IL-1β secretion compared to scramble control. Furthermore, Nigericin induced IL-18 in J77ASC−/− cells, while scramble control led to secretion of similar levels of IL-18 in response to the indicated treatments as non-transfected J77.

**Nigericin Did Not Directly Reduce Bacterial Growth or Alter Phagocytosis in Raw 264.7 Cells**

The effect of nigericin on growth of C. rodentium was examined by OD600 spectrophotometer readings taken at...
FIGURE 4 | Effects of nigericin on expression of inflammasome-associated genes. QIAGEN inflammasome gene array was performed following the manufacturer’s instructions on RNA collected from Raw 264.7 cells treated with nigericin and was compared to untreated cells, following C. rodentium infection. Fold changes display nigericin/untreated.
Nigericin results in bacterial killing in Raw 264.7 cells through a mechanism unrelated to the NRLP3 inflammasome. Raw 264.7 cells were first treated with YVAD as indicated for a total of 3 h. Inoculation of Raw 264.7 with C. rodentium (MOI 1:10) occurred 1 h after initial addition of YVAD. 1.5 h after C. rodentium inoculation, Nigericin (20 µM) or ATP control (2.5 mM) was added to the culture media. Cells were lysed with trizol and RNA extraction and cDNA processing proceeded as described in the methods. qPCR was performed to examine NLRP3, IL-1β, IL-10, Cd40lg, Cita, IL-12, IFN-γ, P38, Nlrp4e, Tab2, TNFα, and Tnfsf11. Samples were controlled against β-actin and Rer1 expression. *p < 0.05.

Nigericin Does Not Alter the Classic NRLP3 Inflammasome Pathway

To better determine the pathways that nigericin alters in Raw 264.7 cells, which may enhance bacterial killing, we performed a gene expression array for inflammatory receptors and cytokines (Figure 4; Supplementary Figure 4). This array indicated time points to exclude a direct effect on bacteria (Figure 3A). Nigericin had no effect on the growth rate of C. rodentium compared to untreated control over 3 h. Next, the effect of nigericin on Raw 264.7 cell phagocytosis was determined by examining uptake of fluorescein-tagged beads. Fluorescein-tagged beads were used instead of bacteria due to the fact that the bacteria would be killed by the macrophage cells under investigation. These macrophage cells are capable of bacterial killing which is altered in response to drug treatments including nigericin. There was no significant change in phagocytosis between NT, nigericin, or ATP control treated cells (p > 0.15; Figures 3B,C). In all samples, it appeared that beads were engulfed by Raw 264.7 cells, suggesting that nigericin impacted bacterial killing but not phagocytosis.
demonstrated altered expression of a series of genes, which were then validated by qPCR (Figure 5). Neither NLRP3 nor its downstream target IL-1β resulted in altered expression profile in C. rodentium infected cells treated with nigericin when compared to untreated (NT), ATP-treated, YVAD-treated, or nigericin in combination with YVAD. While IL-10 and TNFα expression were elevated slightly in response to ATP, no changes were found in response to nigericin. Nigericin treatment resulted in an increase in Cd40lg, Ciita (NLRA), IL-12, IFNγ, Mapk11 (p38), Nlrp4e, and Tab2 as well as a decrease in Tnfsf11. These results led us to propose an alternate model of bacterial killing in cells devoid of inflammasome activity, such as Raw 264.7 and J77ASC−/− (Figure 6). To examine the effect of nigericin on p38 activity we evaluated the changes in phosphorylated p38 by ELISA of cell lysates (Figure 7). Nigericin increased phosphorylated p38 in Raw264.7 and J77ASC−/− but not in J77 cells. To evaluate the involvement of the IL-18-IFNγ-p38 pathway in bacterial killing, we examined the effects of knock-down of IFNγ or p38 by gentamicin assay (Figure 8). Knockdown of IFNγ, p38, and ASC was evaluated by western blot (Figure 8) following 48 h siRNA treatment for both p38 (Figure 8A; AUGAGGAGAUGACCGGAUA) and IFNγ (Figure 8B; UCGAAUGAGUCAGGUAGUA). As expected, knockdown of IFNγ, p38, or both did not alter the bacterial killing associated with ATP control in either J77 or Raw 264.7 cell lines (Figure 8D). Knockdown did not affect bacterial killing with nigericin in J77 cells. However, knockdown of IFNγ, p38, or both resulted in decreased bacterial killing in Raw 264.7 and J77ASC−/− cells treated with nigericin compared to the scramble siRNA control treated with nigericin (p = 0.040), supporting the role of these mediators in the alternative pathway we have identified.

FIGURE 6 | Proposed model of the effects of nigericin on bacterial killing in macrophages deficient of ASC. (1) Caspase-1 is modulated by nigericin via interactions with cathepsin B. Caspase-1 promotes cleavage of the pro-inflammatory cytokine pro-IL-18 (2) to active IL-18, which has been shown to induce upregulation of Cd40lg (3). CD40 is thought to play a key role in inflammatory diseases as hyperactivation of CD40 leads to increased production of pro-inflammatory cytokine, including IL-12 (4). Both IL-12 and IL-18 promote production of IFNγ (5). This cytokine plays a vital role in induction of the MHC class II complex (6), which is critical in macrophage defense against viral, protozoal, and some bacterial infections. IFNγ is an upstream activator of both MAPK and Ciita (7), also known as NLRA. The Ciita/STAT1 pathway is important for MHCII activation and antigen presentation following phagocytosis of bacteria in macrophages, while IFNγ and P38 promote phagocyte and bacterial killing pathways via oxidative burst by increased ROS production (8). Key mediators that were identified by gene array as increased by nigericin are highlighted in pink.
DISCUSSION

While studies that aim to examine microbial killing by macrophages tend to focus on the inflammasome and its downstream target IL-1β, here we have shown that nigericin, a potassium ionophore (28) and NLRP3 activator, remains capable of increasing bacterial killing in J77ASC−/− and Raw 264.7 cells, independent of the classic NLRP3 inflammasome. Raw 264.7 do not express ASC and are therefore not capable of inflammasome activation or function (27), which we have confirmed in this study. Previous studies have suggested that the effects of nigericin on bacterial killing require the inflammasomes (29), while a limited number of studies have demonstrated that the inflammasome is not essential for bacterial clearance (30), although this was tested in a different setting. Interestingly, while nigericin was able to increase microbial killing in cells lacking ASC, YVAD, a caspase-1 inhibitor that blocks the NLRP3 pathway, was able to partially mitigate or reverse this effect (Figures 1B,C). This suggested that caspase-1 plays a role in bacterial killing independent of the NLRP3 inflammasome complex.

As nigericin promotes potassium efflux, and potassium is involved in the promotion of phagocytosis (31), we sought to determine if the effects on bacterial killing were the result of increased host cell death and found this not to be the case. Our results demonstrated that nigericin did not alter C. rodentium growth rates directly (Figure 3A) and did not result in statistically significant changes in phagocytosis in Raw 264.7 cells (Figures 3B,C). To identify key targets involved in response to nigericin we ran an inflammasome gene array of Raw 264.7 cells treated with nigericin and compared expression of these genes to untreated (NT) cells (Figure 4). Validation of expression of key target genes demonstrated that nigericin resulted in increased expression of Cd40lg, Ciita (NLRA), IL-12, IFNγ, Mapk11 (p38), Nlrp4e, and Tab2 as well as a decrease in Tnfsf11 in nigericin-treated cells (Figure 5). Based on these results we hypothesized a possible model of nigericin-mediated bacterial killing without involvement of the inflammasome (Figure 6). Caspase-1 has previously been shown to be modulated by nigericin via interactions with cathepsin B (32). Interestingly, caspase-1 promotes cleavage of the pro-inflammatory cytokine pro-IL-18 to active IL-18. Activation of IL-18 leads to up-regulation of Cd40lg (33), a cytokine which was increased in response to nigericin in the current study. CD40 is thought to play a key role in inflammatory diseases as hyperactivation of CD40 leads to increased production of pro-inflammatory cytokines, including IL-12 (34). IL-12 was also found to be increased in response to nigericin. Results from the current study support previous research indicating that both IL-12 and IL-18 promote production of IFNγ. This cytokine plays a vital role in induction of the MHC class II complex, which is critical in macrophage defense against viral, protozoal, and some bacterial infections (35). IFNγ is an upstream activator of both MAPK and ciita, also known as NLRA. Both p38 and ciita were increased following nigericin treatment, adding further support for our hypothesized pathway. The Ciita/STAT1 pathway is important for MHCIi activation and antigen presentation following phagocytosis of bacteria in macrophages (36), while IFNγ induction of p38 promotes phagocyte and bacterial killing pathways via oxidative burst by increased ROS production (37, 38). Interestingly, we support this model by demonstrating that while IL-1β secretion was not affected in Raw 264.7 or J77ASC−/− cells, secretion of a closely related interleukin, IL-18, was increased in these cells in response to nigericin (Figure 2). We further showed that phosphorylated p38 was increased in these cells in response to nigericin indicating increased activity (Figure 7). Knockdown of the key pathway intermediates p38, IFNγ, or both, results in reduced bacterial killing only in cells lacking ASC (Figure 8), indicating this pathway is indeed involved as an alternate mechanisms of bacterial killing to NLRP3/ASC inflammasome complex pathways. This work should stimulate further investigation into alternative, non-inflammasome mediated pathways for immune activation and bacterial killing in macrophages.

We have demonstrated here the potential for pathways alternate to the classic NLRP3 inflammasome in bacterial killing in macrophage cells lacking an active inflammasome complex by utilizing nigericin in vitro. Macrophages play a key role in clearance of pathogenic and pathobiont microorganisms in inflammatory disease (39). Therefore, this study has the potential to impact a number of inflammatory diseases including cystic fibrosis, inflammatory bowel diseases, infection, and even cancer, as this could introduce innovative treatment options to mitigate disease pathogenesis by targeting multiple immune pathways to improve efficiency of bacterial clearance (40). As current...
FIGURE 8 | Knockdown of P38 and interferon-gamma ameliorates the effects of nigericin bacterial killing. Dharmacon siRNA directed to P38, interferon-gamma, both P38 and interferon-gamma, or ASC was carried out for 48 h prior to beginning infection and drug treatments. Cells were first treated with YVAD as indicated for a total of 3 h. Inoculation of cells with C. rodentium (MOI 1:10) occurred 1 h after initial addition of YVAD. 1.5 h after C. rodentium inoculation, Nigericin (20 µM) or ATP control (2.5 mM) was added to the culture media. Cells were lysed with trizol and RNA extraction and cDNA processing proceeded as described in the methods. Knockdown was confirmed by western blot for (A) sip38(P38), (B) siIFNγ, or (C) siASC. (D) Gentamicin protection assays were performed to examine bacterial killing in Raw 264.7, J77, and J77ASC−/− cell lines. *p < 0.05.
studies are focused on targeting the NLRP3 inflammasome alone in these diseases, understanding the alternate inflammatory pathways involved in bacterial clearance within a macrophage cell system will aid in our ability to identify new methods of modulating immune response.

**AUTHOR CONTRIBUTIONS**

HA, MB-J, and EW conceived and designed the experiments. HA, MB-J, and RC performed the experiments. HA and MB-J were responsible for figures preparation and statistical analyses. HA and EW drafted the manuscript. All authors approved the final version.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02296/full#supplementary-material

**Supplementary Figure 1** | Growth response of Raw 264.7 cells to the indicated doses of ATP, YVAD, nigericin, and gentamicin was examined by manual counting using haemocytometer at indicated times and by trypan blue exclusion.

**REFERENCES**

1. DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. (2016) 22:1137–50. doi: 10.1097/MIB.0000000000000750
2. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. (2009) 9:313–23. doi: 10.1038/nri2515
3. Ruel J, Ruane D, Mehandru S, Gower-Rousseau C, Colombel JF. IB D across generations. J Immunol. (2015) 194:3937–52. doi: 10.4049/jimmunol.1402658
4. Borenshtein D, McBee ME, Schauer DB. Utility of the Citrobacter rodentium + efflux agonists study in an infection model in laboratory mice. Curr Opin Gastroenterol. (2008) 24:32–7. doi: 10.1097/MOG.0b013e3282b260f6
5. Weiss G, Schaab U. Macrophage defense mechanisms against intracellular bacteria. Immunol Rev. (2015) 264:182–203. doi: 10.1111/imr.12266
6. Bording-Jørgensen M, Alipour M, Danesh G, Wine E. The inflammasome in chronic inflammatory diseases: current perspectives. J Inflamm Res. (2015) 8:15–27. doi: 10.2147/JIR.S51250
7. Bufe B, Zufall F. The sensing of bacteria: emerging principles for the detection of signal sequences by formyl peptide receptors. Biochim. Biophys. Acta 1725:17217–23. doi: 10.1074/jbc.M303837200
8. Schroder K, Tschopp J. The inflammasomes. Cell 2010.2013:859145. doi: 10.1155/2013/859145
9. Armstrong et al. NLRP3 in Macrophage Bacterial Killing
10. LaRock CN, Cookson BT. The Yersinia virulence effector YopM binds caspase-1 to arrest inflammasome assembly and processing. Cell Host Microbe. (2012) 17:799–805. doi: 10.1016/j.chom.2012.10.020
11. Willingham SB, Allen IC, Bergstrahl DT, Brickey WJ, Huang MT, Taxman DJ, et al. NLRP3 inflammasome regulates GSDMD N-terminal fragment levels in response to caspase-1 activation in vivo. J Immunol. (2019) 193:2008–15. doi: 10.4049/jimmunol.1900138
12. Shankar SK, Suvarna S, Nigam R, Harikrishnan K, Sein C, et al. NLRP3 inflammasome regulation by Osteopontin mediates Caspase-1-dependent cell death. J Immunol. (2016) 197:102–9. doi: 10.4049/jimmunol.1600150
13. Dorfleuter A, Talbott SJ, Bryan NB, Funya KN, Rellick SL, Reed JC, et al. A Shope Fibroma virus PYRIN-only protein modulates the host immune response. Virus Genes. (2007) 35:685–94. doi: 10.1007/s11262-007-9141-9
14. Niuo M, Shinohara ML. NLRP3 inflammasome and MS/EAE. Autoimmune Immunol. Dis. (2013) 2013:859145. doi: 10.1155/2013/859145
15. Zhang L, Liu X, Cao X. Extracellular pattern recognition molecules in health and diseases. Cell Physiol Biochem. (2004) 279:17217–23. doi: 10.1074/jbc.M303837200
16. Zhao Y, Kinio A, Saleh M. Functions of NO-induced receptors in human diseases. Front Immunol. (2013) 4:333. doi: 10.3389/fimmu.2013.00333
17. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, McDonald K, Speert D, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. (2009) 183:787–91. doi: 10.4049/jimmunol.0901363
18. Franchi L, Munoz-Planillo R, Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. (2012) 13:325–32. doi: 10.1038/ni.2231
19. Kim EH, Park MJ, Park S, Lee ES. Increased expression of the NLRP3 inflammasome components in patients with Behcet’s disease. J Inflamm. (2015) 12:41. doi: 10.1186/s12950-015-0086-z
20. Weiss G, Schaab U. Macrophage defense mechanisms against intracellular bacteria. Immunol Rev. (2015) 264:182–203. doi: 10.1111/imr.12266
21. Valea D, Kuchرج A, Derricotte V, Franchi L, Munoz-Planillo R, Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. (2012) 13:325–32. doi: 10.1038/ni.2231
22. Kim EH, Park MJ, Park S, Lee ES. Increased expression of the NLRP3 inflammasome components in patients with Behcet’s disease. J Inflamm. (2015) 12:41. doi: 10.1186/s12950-015-0086-z
23. Park JH, Jeong SY, Choi AJ, Kim SJ. Lipopolysaccharide directly stimulates caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways. J Immunol. (2009) 183:2008–15. doi: 10.4049/jimmunol.0901363
24. Borenshtein D, McBee ME, Schauer DB. Utility of the Citrobacter rodentium + efflux agonists study in an infection model in laboratory mice. Curr Opin Gastroenterol. (2008) 24:32–7. doi: 10.1097/MOG.0b013e3282b260f6
25. Weiss G, Schaab U. Macrophage defense mechanisms against intracellular bacteria. Immunol Rev. (2015) 264:182–203. doi: 10.1111/imr.12266
hyperplasia and attaching-effacing lesions. Am J Pathol. (2010) 177:1320–32. doi: 10.2353/ajpath.2010.091068
26. Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, et al. Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget. (2013) 4:6991–704. doi: 10.18632/oncotarget.975
27. Pelegrin P, Barroso-Gutierrez C, Surprenant A. P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J Immunol. (2008) 180:7147–57. doi: 10.4049/jimmunol.180.11.7147
28. Locovei S, Scemes E, Qiu F, Spray DC, Dahl G. Pannexin1 is part of the pore forming unit of the P2X(7) receptor death complex. FEBS Lett. (2007) 581:483–8. doi: 10.1016/j.febslet.2006.12.056
29. Maritathan S, Weiss DS, Newton K, McBride J, O’Rourke K, Roose-Girma M, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. (2006) 440:228–32. doi: 10.1038/nature04515
30. Liu N, Belperron AA, Booth CJ, Bockenstedt LK. The caspase 1 inflammasome is not required for control of murine Lyme borreliosis. Infect Immun. (2009) 77:3320–7. doi: 10.1128/IAI.00100-09
31. Ince C, Coremans JM, Ypey DL, Leijh PC, Verveen AA, van Furth R. Phagocytosis by human macrophages is accompanied by changes in ionic channel currents. J Cell Biol. (1988) 106:1873–8. doi: 10.1083/jcb.106.6.1873
32. Hentze H, Lin XY, Choi MS, Porter AG. Critical role for cathepsin B in mediating caspase-1-dependent interleukin-18 maturation and caspase-1-independent necrosis triggered by the microbial toxin nigericin. Cell Death Differ. (2003) 10:956–68. doi: 10.1038/sj.cdd.4401264
33. Hoshino T, Yagita H, Ortaldo JR, Wiltrout RH, Young HA. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand. (CD154) expression on CD4+ T cells. Eur J Immunol. (2000) 30:1998–2006. doi: 10.1002/1521-4141(200007)30:7<1998::AID-IMMU1998>3.0.CO;2-U
34. Chen J, Chen L, Wang G, Tang H. Cholesterol-dependent and -independent CD40 internalization and signaling activation in cardiovascular endothelial cells. Arterioscler Thromb Vasc Biol. (2007) 27:2005–13. doi: 10.1161/ATVBAHA.107.145961
35. Steimle V, Siegrist CA, Mottet A, Lisovska-Grospiere B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. (1994) 265:106–9. doi: 10.1126/science.8016643
36. Barbaro Ade L, Tosi G, Frumonto G, Bruschi E, D’Agostino A, Valle MT, et al. Block of Stat-1 activation in macrophages phagocytosing bacteria causes reduced transcription of CIITA and consequent impaired antigen presentation. Eur J Immunol. (2002) 32:1309–18. doi: 10.1002/1521-4141(20020532<1309::AID-IMMU1309>3.0.CO;2-4
37. Gordon MA, Jack DL, Dockrell DH, Lee ME, Read RC. Gamma interferon enhances internalization and early non-oxidative killing of Salmonella enterica serovar Typhimurium by human macrophages and modifies cytokine responses. Infect Immun. (2005) 73:3445–52. doi: 10.1128/IAI.73.6.3445-345.2.2005
38. Wang Y, Zeigler MM, Lam GK, Hunter MG, Eubank TD, Khramtsov VV, et al. The role of the NADPH oxidase complex, p38 MAPK, and Akt in regulating human monocyte/macrophage survival. Am J Respir Cell Mol Biol. (2007) 36:68–77. doi: 10.1165/rcmb.2006-0165OC
39. Smith AM, Rahaman FZ, Hayee B, Graham SJ, Marks DJ, Sewell GW, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn’s disease. J Exp Med. (2009) 206:1883–97. doi: 10.1084/jem.20091233
40. Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov. (2018) 17:688. doi: 10.1038/nrd.2018.97

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Armstrong, Bording-Jorgensen, Chan and Wine. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.